Symphony Technology Group buys majority stake in ImpactRx

ImpactRx remains part owned by the venture capital arm of drug company Merck and continues to be led by president and CEO Richard Altus (pictured).

Altus said the acquisition and investment by Symphony Technology Group will allow for further development of its capabilities to meet clients’ emerging analytical needs.

He said: “Brand teams are facing increasingly complex challenges. Understanding what drives brand performance, through all stages of the life cycle, is more critical today than it ever was.”